Initial endocrine therapy tops chemotherapy for HR+/HER2- metastatic breast cancer

Study supports international guidelines that advocate the use of endocrine therapy as the preferred option for HR+/HER2- metastatic breast cancer.
Study supports international guidelines that advocate the use of endocrine therapy as the preferred option for HR+/HER2- metastatic breast cancer.